As of November 6, 2026, Travere Therapeutics, Inc. is a publicly traded company (Nasdaq: TVTX); its largest reported holder is Fidelity (FMR), with 6.1% on Schedule 13G/A of November 5, 2026, then Bank of America (5.8%). The largest insider holding is Eric M. Dube, the chief executive and a director, with 432,886 shares (0.45% of shares outstanding), per Form 4 of October 19, 2026 (Schedule 13G/A, November 5, 2026).
Is this your company?
About to sign with, pay or invest in Travere Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Travere Therapeutics, Inc. a real, registered company?
- Travere Therapeutics, Inc. files with the SEC under CIK 1438533 (its SEC filings).
- Its shares are listed under the ticker TVTX on Nasdaq (SEC company record).
- Incorporated in California; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under TRAVERE THERAPEUTICS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Bradley L. Campbell, President and Chief Executive Officer (Form 8-K filed 2026-09-21). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are Travere Therapeutics, Inc.'s owners and officers?
Travere Therapeutics, Inc.: incorporated in California; business address in San Diego, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 6.1% |
| Schedule 13G/A, 2026-08-14 | Armistice Capital, LLC | 1.67% |
| Schedule 13G, 2026-08-12 | Bank Of America Corp /De/ | 5.8% |
| Schedule 13G, 2026-08-07 | State Street Corporation | 4.6% |
| Schedule 13G/A, 2026-08-06 | Fmr LLC | 7.7% |
| Schedule 13G, 2026-05-15 | Armistice Capital, LLC | 5.27% |
| Schedule 13G, 2026-04-30 | Vanguard Capital Management | 5.09% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Armistice Capital, LLC | 4.21% |
| Schedule 13G/A, 2026-02-17 | Perceptive Advisors LLC | 4.8% |
| Schedule 13G/A, 2026-02-13 | Macquarie Group Limited | 0% |
| Schedule 13G, 2026-02-09 | State Street Corporation | 5.3% |
Questions about who owns Travere Therapeutics, Inc.
Who owns Travere Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Travere Therapeutics, Inc.: Fmr LLC (6.1%, Schedule 13G/A, filed 2026-11-05), Bank Of America Corp /De/ (5.8%, Schedule 13G, filed 2026-08-12) and Vanguard Capital Management (5.09%, Schedule 13G, filed 2026-04-30).
Who are the largest shareholders of Travere Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Travere Therapeutics, Inc. on this page are Fmr LLC (6.1%), Bank Of America Corp /De/ (5.8%) and Vanguard Capital Management (5.09%).
When did Fmr LLC buy into Travere Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G/A, filed 2026-08-06, reporting 7.7%; its latest, Schedule 13G/A filed 2026-11-05, reports 6.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Travere Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Travere Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Travere Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
21 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-21 | Bradley L. Campbell | President and Chief Executive Officer | appointed | |
| Form 8-K, 2026-07-09 | Sandra Calvin | departed | ||
| Form 8-K, 2026-06-16 | William Rote | Chief Research Officer | departed | 2027-02-17 |
| Form 8-K, 2026-06-16 | Jula Inrig | Chief Medical Officer | appointed | 2026-07-01 |
Which insiders own Travere Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 432,886 shares (0.45% of shares outstanding) (Form 4, 2026-10-19).
- , the executive vice president and chief commercial officer: 117,066 shares (0.12% of shares outstanding) (Form 4, 2026-09-17).
- , the general counsel and chief legal officer: 105,389 shares (0.11% of shares outstanding) (Form 4, 2026-09-17).
- , the executive vice president and head of r: 100,491 shares (0.10% of shares outstanding) (Form 4, 2026-09-17).
- , the chief research officer: 98,197 shares (0.10% of shares outstanding) (Form 4, 2026-09-17).
Shares outstanding: 95,992,155 as of 2026-10-28, from the company's latest SEC cover page.
How much has Travere Therapeutics, Inc. raised?
No fundraising or offering filing from Travere Therapeutics, Inc. is on file with us.
Keep reading
More on Travere Therapeutics, Inc. and the records around it.
Travere Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Sep 2026
Companies that share a holder
- Macquarie Group Limited also filed stake reports on 14 other companies: Artivion Inc (Feb 2026), Imax Corp (Feb 2026), Kaiser Aluminum Corp (Feb 2026)
- Perceptive Advisors LLC also filed stake reports on 57 other companies: Nautilus Biotechnology, Inc. (Nov 2026), Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026)
- BANK OF AMERICA CORP /DE/ also filed stake reports on 74 other companies: BlackRock 2037 Municipal Target Term Trust (Nov 2026), TRIMAS CORP (Nov 2026), PIMCO CALIFORNIA MUNICIPAL INCOME FUND (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/travere-therapeutics